Previous 10 | Next 10 |
CLEVELAND, Jan. 14, 2020 (GLOBE NEWSWIRE) -- Athersys, Inc. (NASDAQ: ATHX) announced today the one-year follow-up summary results from its exploratory clinical study of the intravenous administration of MultiStem® cell therapy to treat patients who are suffering from acute respiratory ...
In late January 2019, as I gathered information for my monthly Stem Cell News and Analysis newsletter , I came across an obscure (at least in the U.S.) Australian-based company in the regenerative medicine space that I had never heard of before. Unknown to me, this company had accomplished ...
We've run through 10 different sectors or styles of investing in our year-end Marketplace Roundtable series. You can review the full list of roundtables at the end of this article in case you'd like to catch up on any specific angle. As we do every year, we conclude the series with the com...
2019 finishes with an extra kick for investors. Part of that is the continued strong run of the market, erasing memories of last year's near bear market and extending the decade-long bull. There also are plenty of market headlines and events that have sprung over the end of the year, from Ph...
Athersys (NASDAQ: ATHX ) has turned 12% lower after hours, a move attributed to reporter Adam Feuerstein's reaction to a new filing of a stock purchase agreement. More news on: Athersys, Inc., Healthcare stocks news, Stocks on the move, Read more ...
The following slide deck was published by Athersys, Inc. in conjunction with their 2019 Q3 earnings Read more ...
CLEVELAND, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq: ATHX) announced today that its collaborator in Japan, HEALIOS K.K. (“Healios”) received notification this week from the Pharmaceutical Affairs and Food Sanitation Council (“PAFSC”) that its acut...
Image source: The Motley Fool. Athersys (NASDAQ: ATHX) Q3 2019 Earnings Call Nov 06, 2019 , 4:30 p.m. ET Operator Continue reading
Athersys, Inc. (ATHX) Q3 2019 Results Earnings Conference Call November 6, 2019, 04:30 PM ET Company Participants Karen Hunady - Director, Corporate Communications and Investor Relations Laura Campbell - Senior Vice President, Finance Gil Van Bokkelen - Founder, Chairman and Chie...
Athersys (NASDAQ: ATHX ): Q3 GAAP EPS of -$0.08 beats by $0.01 . Cash and equivalents of $40.4M. Press Release More news on: Athersys, Inc., Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
Athersys, Inc. (OTC: ATHX), a regenerative medicine company developing MultiStem ® (invimestrocel) cell therapy for critical care indications, announced financial results for the three and nine months ended September 30, 2023 and provided a business update. Third Quarter 2023 and...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Athersys, Inc. (Nasdaq: ATHX), (“Athersys” or the “Company”) a cell therapy and regenerative medicine company developing MultiStem ® (invimestrocel) for critical care indications, announces it has entered into a warrant exercise inducement offer letter to ra...